Abstract
Diabetes is the third leading cause of death in the US1. Prior to the discovery of insulin by Banting and Best in 1921, most diabetic mortality resulted from hyperglycemic ketoacidosis. Since that time, cardiovascular disease secondary to the diabetic state has become the leading cause of death in the diabetic population. While insulin replacement therapy appears sufficient to prevent severe hyperglycemic episodes, control is not sufficient to avert cardiovascular complications. Indeed, there is considerable evidence that insulin, itself, may play a deleterious role in the adverse cardiovascular sequelae associated with diabetes. Under normal conditions, the body releases only that amount of insulin required for control of blood glucose. In contrast, replacement therapy for the diabetic individual involves a bolus of insulin, resulting in early excessive levels followed by declining levels with time.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kannei, W.B. and McGee, D.L.,1979, Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035–2038.
Ackerman, D. and Heinsen, H.A.,1935, Uber die physiologische Wirkung des asterubins and anderer, zum tiel neu dargestellter, schwefelhaltiger guanidinderivate. Z Physiol. Chem. 235:115–121.
Macallum, A.B., and Silvertz, C., 1942, The Potentiation of insulin by sulfones. Can. Chem. Process. 26:669.
Kulakowski, E.C., Maturo, J., 1984, Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem. Pharmacol. 33:2835–2838.
Lampson, W.G., Kramer, J.H., and Schaffer, S.W. Potentiation of the actions of insulin by taurine. Can. J. Physiol. Pharmacol. 61: 457–463.
Kulakowski, E.C., Matsuro, J., and Schaffer, S.W., 1985, The low affinity taurine-binding protein may be related to the insulin receptor. In Taurine: Biological Actions and Clinical Perspectives, eds. Oja, S.S., Ahtee, L., Kontro, P., and Paasonen, M.K. Allan R. Liss, Inc., New York, pp. 126–136.
Shimuza, T., Shimizu, S., Nagami, S., and Wada, M., 1960, Effect of hypotaurine and cysteine on alloxan-and dehydroxyascorbic acid-diabetes. Niigata Med. J. 74:931–939.
Silaeva, T.Y., Dokshina, G.A., Yartsev, E.I., Yakoleva, V.V., and Arkhangelskaya, T.E., 1976, The effect of taurine on the carbohydrate metabolism of diabetic animals. Prob. Endokrinol. 22:99–103.
Tokunaga, H., Yoneda, Y., and Kuriyama, K., 1979, Protective actions of taurine against streptozotocin-induced hyperglycemia. Biochem. Pharmacol. 28:2807–2811.
Petty, M.A., Kintz, J., DiFrancesco, G.F., 1990, The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. Eur. J. Pharmacol. 180:119–127.
Ramanadham, S. and Tenner, T.E., Jr., 1987, Alterations in the myocardial ß-adrenoceptor system of streptozotocin diabetic rats. Europ. J. Pharmacol. 136(3): 377–390.
Alipui, C., Ramos, K. and Tenner, T.E., Jr., 1993, Alterations of aortic smooth muscle cell proliferation in diabetes mellitus. Cardiovascular Research 27: 1229–1232.
Davis, R.L., Lavine, C.L., Arredondo, M.A., McMahon, P., and Tenner, T.E., Jr., 2002, Differential indicators of diabetes-induced oxidative stress in New Zealand White rabbits: Role of dietary vitamin E supplementation. Experimental Diabetes Research 3: 1–7.
Lombardini, J.B., 1986, Taurine levels in blood and urine of vitamin B6 deficient and estrogen-treated rats. Biochem. Med. 35:125–131.
Goodman, H.O., Shihabi, Z.K., 1990, Supplemental taurine in diabetic rats: effects on plasma glucose and triglycerides. Biochem. Med. Metab. Biol. 43:1–9.
Martensson, J., Hermansson, G., 1984, Sulfur amino acid metabolism in juvenile onset nonketotic and ketotic diabetic patients. Metabolism 33:425–428.
Franconi, F., Bennardini, F., Mattana, A., Miceli, M., Ciuti, M., Mian, M., Gironi, A., Anichini, R. and Seghieri, G., 1995, Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am. J. Clin. Nutr. 61(5):1115–1119.
Elizarova, E.P. and Nedosugova, L.V., 1996, First experience in taurine administration for diabetes mellitus. Adv. Exp. Med. Biol. 403: 583–587.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tenner, T.E., Zhang, X.J., Lombardini, J.B. (2003). Hypoglycemic Effects of Taurine in the Alloxan-Treated Rabbit, a Model for Type 1 Diabetes. In: Lombardini, J.B., Schaffer, S.W., Azuma, J. (eds) Taurine 5. Advances in Experimental Medicine and Biology, vol 526. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0077-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0077-3_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4913-6
Online ISBN: 978-1-4615-0077-3
eBook Packages: Springer Book Archive